108 related articles for article (PubMed ID: 12089783)
41. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
42. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
43. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
44. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.
Guerra E; Cimadamore A; Simeone P; Vacca G; Lattanzio R; Botti G; Gatta V; D'Aurora M; Simionati B; Piantelli M; Alberti S
BMC Cancer; 2016 Aug; 16():649. PubMed ID: 27538498
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.
Chozick BS; Benzil DL; Stopa EG; Pezzullo JC; Knuckey NW; Epstein MH; Finkelstein SD; Finch PW
J Neurooncol; 1996 Feb; 27(2):117-26. PubMed ID: 8699233
[TBL] [Abstract][Full Text] [Related]
46. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
47. [Tumor suppressor gene p53. Theoretical principles and their significance for pathology].
Poremba C; Bankfalvi A; Dockhorn-Dworniczak B
Pathologe; 1996 May; 17(3):181-8. PubMed ID: 8710788
[TBL] [Abstract][Full Text] [Related]
48. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of cytosolic p53 protein in breast cancer.
Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
[TBL] [Abstract][Full Text] [Related]
50. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
51. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic and molecular features associated with patient age in gastric cancer.
Seo JY; Jin EH; Jo HJ; Yoon H; Shin CM; Park YS; Kim N; Jung HC; Lee DH
World J Gastroenterol; 2015 Jun; 21(22):6905-13. PubMed ID: 26078567
[TBL] [Abstract][Full Text] [Related]
53. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
Schmidt M; Bachhuber A; Victor A; Steiner E; Mahlke M; Lehr HA; Pilch H; Weikel W; Knapstein PG
J Cancer Res Clin Oncol; 2003 May; 129(5):295-302. PubMed ID: 12715164
[TBL] [Abstract][Full Text] [Related]
54. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
[TBL] [Abstract][Full Text] [Related]
55. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2.
Dabbs DJ
Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697
[TBL] [Abstract][Full Text] [Related]
56. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
57. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
58. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
Pu T; Guo P; Qiu Y; Chen S; Yang L; Sun L; Ye F; Bu H
Int J Clin Exp Pathol; 2015; 8(9):10565-74. PubMed ID: 26617766
[TBL] [Abstract][Full Text] [Related]
59. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases.
Nagao T; Gaffey TA; Serizawa H; Sugano I; Ishida Y; Yamazaki K; Tokashiki R; Yoshida T; Minato H; Kay PA; Lewis JE
Mod Pathol; 2003 Dec; 16(12):1265-72. PubMed ID: 14681328
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
